Pevion Biotech hires new ceo
Also secures CHF10m of financing
Prior to joining Pevion, Kueppers was ceo of Pieris, a Munich-based biotechnology company, which he successfully restructured and refinanced, raising a total US$45m. Before joining the biotech industry, he spent several years in the International Operations of BASF Pharma (now Abbott Labs) and was a management consultant with the global healthcare team of AT Kearney in London.
The company has also secured further financing of CHF10m from its existing investors, BZ Bank, BB Biotech Ventures and Core Capital.
Pevion says it plans to raise additional financing over the next 12 months to broaden its pipeline.
‘Pevion has reached an important stage in its development as its candidate products reach for critical milestones. This financing commitment should take the company a long way towards achieving further product validation,’ said Joseph Manko of BZ Bank and member of the Board of Directors.
You may also like
Research & Development
Scientists develop new technique to fight antimicrobial resistance
The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development
Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures
A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models
Regulatory
WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants
The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Britain's biotech potential (part II): world-class science, second-class support?
In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Regulatory
FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection
The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026